title: Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity.
abstract: In individuals with multiple sclerosis (MS) spasticity, associated symptoms such as spasms, pain, mobility restrictions and sleep disturbances can interfere with the ability to perform activities of daily living and reduce quality of life (QoL). Recent cross-sectional studies from Europe have confirmed that advancing severity of MS spasticity correlates directly with worsening QoL. The treatment effect of Sativex(®) (GW Pharmaceuticals PLC, Porton Down, UK; Laboratorios Almirall, SA, Barcelona, Spain) on QoL has been evaluated in randomized controlled trials, observational studies conducted under everyday clinical practice conditions and a survey in long-term users. Symptomatic relief of MS spasticity in responders to Sativex was associated with quantifiable improvements in QoL and activities of daily living that were maintained over time. Benefits were perceived by both patients and caregivers.
authors.affiliation: Department of Neurology, Hospital Clínico San Carlos, Madrid, Spain.
authors.forename: Rafael
authors.initials: R
authors.lastname: Arroyo
authors.forename: Carlos
authors.initials: C
authors.lastname: Vila
authors.forename: Kerry L
authors.initials: KL
authors.lastname: Dechant
mesh_terms: D000203:Activities of Daily Living; D002185:Cannabidiol; D013759:Dronabinol; D004338:Drug Combinations; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy*; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology; D017063:Outcome Assessment, Health Care; D010936:Plant Extracts / Q000627:therapeutic use*; D011788:Quality of Life
chemical_list: D004338:Drug Combinations; D010936:Plant Extracts; D002185:Cannabidiol; D013759:Dronabinol; C587251:nabiximols
keywords: Sativex®; activities of daily living; multiple sclerosis; quality of life; spasticity